UWF’s Rodney Guttmann received a second NIH grant this year, thus funding an additional three years of research on blood-based biomarkers that may help diagnose Alzheimer’s earlier and allow for more effective and impactful interventions and treatments.

Guttman is director of UWF’s Center on Aging. His current work, funded by the National Institute on Aging through NIH R15 grants, focuses on early Alzheimer’s detection through advanced phage display technology. He has also partnered with Avanir and Otsuka to develop patented therapeutics, including a membrane-permeable peptide capable of calpain inhibition and monoclonal antibodies targeting pathological forms of calcineurin.

• Rodney Guttmann